Viral replication is a complex process by which viruses use host cell machinery to produce new viral particles. The life cycle generally involves several key stages: attachment, penetration, uncoating, replication and transcription, translation, assembly, and release. Upon attaching to specific host cell receptors, viruses penetrate the cell either through direct fusion with the cell membrane or via endocytosis. Once inside, the virus undergoes uncoating, freeing its genetic material. Replication and transcription involve the synthesis of viral RNA or DNA using host cell machinery. Viral proteins are then produced through translation of the viral genome. These components are assembled into new virus particles, often in specialized cellular compartments. Release can occur through cell lysis, where the host cell is destroyed, or through a more subtle process called budding, where new virus particles exit the cell without causing immediate cell death. Understanding viral replication is crucial for developing antiviral strategies, including drugs that target various stages of the viral life cycle. Research in this area continues to uncover the intricacies of host-virus interactions, aiding the development of interventions to combat viral infections.
Title : The importance of post-marketing surveillance and real-world data: For a product to be successful
Regina Au, BioMarketing Insight, United States
Title : A promising novel approach to DNA vaccines
Khursheed Anwer, IMUNON, United States
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : Post COVID-19 syndrome is associated with sex and severity of first COVID-19 episode in Honduras
Manuel Antonio Sierra Santos, Central American Technological University, Honduras
Title : Homology analysis of MPXV and VACV peptides underscores the need to consider both MPXV clades for vaccine development
Lara Isis Teodoro, Mayo Clinic, United States
Title : Establishing a platform method for physical appearance assessment of new parenteral pharmaceuticals
Ying Wan, Merck & Co., United States
Title : Development of a novel multi-component vaccine to address the burden of otitis media in high-risk populations
Ayesha Zahid, Griffith University, Australia
Title : High seroprevalence of RSV antibodies in adults indicates potential undetected transmission and requires further public health assessment
Lara Isis Teodoro, Mayo Clinic, United States
Title : New biomarkers in leishmania major vaccine development
Negar Seyed, Pasteur Institute of Iran, Iran (Islamic Republic of)
Title : Development of a platform UPLC-CAD method for high-throughput lipid quantitation and characterization in novel mRNA LNPs
Janet Muzulu, Sanofi, United States